Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
STRATA Skin Sciences (NASDAQ: SSKN) on Oct 3, 2025 highlighted peer‑reviewed evidence validating its XTRAC® 308 nm Excimer Laser as a safe, effective therapy for localized atopic dermatitis.
The release notes the AMA has expanded excimer laser indications to inflammatory and autoimmune skin diseases, enabling Medicare, Medicaid and private payer reimbursement for atopic dermatitis. The PR cites clinical results: 81% itch reduction (Baltás et al.), randomized trial equivalence/superiority vs. clobetasol with longer durability (Brenninkmeijer et al.), and in refractory hand/foot eczema 69% severity reduction, 70% symptom score reduction, 87% clear/almost clear, and average remission of 11.3 months (Shroff et al.). The company emphasizes targeted, steroid‑sparing treatment benefits and reduced UV exposure versus whole‑body phototherapy.
STRATA Skin Sciences (NASDAQ: SSKN) il 3 ottobre 2025 ha messo in evidenza prove peer‑reviewed che convalidano il suo XTRAC® 308 nm Excimer Laser come terapia sicura ed efficace per dermatite atopica localizzata.
Il comunicato rileva che l'AMA ha ampliato le indicazioni della laserterapia ad eccimeri a malattie della pelle infiammatorie e autoimmuni, permettendo il rimborso da parte di Medicare, Medicaid e assicurazioni private per la dermatite atopica. Il comunicato stampa cita risultati clinici: 81% di riduzione del prurito (Baltás et al.), equivalenza/superiorità in test randomizzati rispetto al clobetasolo con maggiore durabilità (Brenninkmeijer et al.), e nell’eczema refrattario di mani/piedi 69% di riduzione della gravità, 70% di riduzione del punteggio dei sintomi, 87% di chiarimento/quasi chiarimento e una remissione media di 11,3 mesi (Shroff et al.). L’azienda sottolinea i benefici di un trattamento mirato, senza steroidi, e una ridotta esposizione UV rispetto alla fototerapia dell’intero corpo.
STRATA Skin Sciences (NASDAQ: SSKN) el 3 de octubre de 2025 destacó evidencia revisada por pares que valida su XTRAC® 308 nm Excimer Laser como una terapia segura y eficaz para la dermatitis atópica localizada.
El comunicado señala que la AMA ha ampliado las indicaciones del láser de excímeros a enfermedades de la piel inflamatorias y autoinmunes, permitiendo el reembolso por Medicare, Medicaid y aseguradoras privadas para la dermatitis atópica. El PR cita resultados clínicos: 81% de reducción de la picazón (Baltás et al.), equivalencia/superioridad en ensayos aleatorizados frente al clobetasol con mayor durabilidad (Brenninkmeijer et al.), y en la eczema refractario de manos/pies 69% de reducción de la gravedad, 70% de reducción de la puntuación de síntomas, 87% de claridad o casi claridad, y una remisión media de 11,3 meses (Shroff et al.). La empresa enfatiza beneficios de tratamiento dirigido, reducción de esteroides y menor exposición a UV frente a la fototerapia de cuerpo entero.
STRATA Skin Sciences (NYSE: SSKN)는 2025년 10월 3일에 국소화된 아토피 피부염에 대해 안전하고 효과적인 치료법으로 XTRAC® 308 nm 엑시머 레이저를 입증하는 동료 심사 증거를 강조했습니다.
보도자료에 따르면 AMA가 엑시머 레이저의 적응증을 염증성 및 자가면역성 피부 질환으로 확장하여 아토피 피부염에 대한 메디케어, 메디케이드 및 민간 보험의 상환을 가능하게 한다고 합니다. PR은 임상 결과를 인용합니다: 81%의 가려움 감소(Baltás 외), 무작위 시험에서 클로베타솔에 대한 동등성/우수성 및 더 긴 지속성(Brenninkmeijer 외), 그리고 난치성 손/발 습진에서 69%의 중증도 감소, 70%의 증상 점수 감소, 87%의 개선/거의 개선, 그리고 평균 재발 기간 11.3개월(Shroff 외). 회사는 표적 치료의 스테로이드 절감 및 전신 자외선 노출 감소를 강조합니다.
STRATA Skin Sciences (NASDAQ: SSKN) le 3 octobre 2025 a mis en évidence des preuves par revue par les pairs validant son XTRAC® 308 nm Excimer Laser comme thérapie sûre et efficace pour la dermatite atopique localisée.
Le communiqué indique que AMA a étendu les indications du laser excimer à des maladies cutanées inflammatoires et auto‑immunes, permettant le remboursement par Medicare, Medicaid et les assureurs privés pour la dermatite atopique. Le PR cite des résultats cliniques : 81% de réduction des démangeaisons (Baltás et al.), équivalence/supériorité dans des essais randomisés vs le clobétasol avec une durabilité accrue (Brenninkmeijer et al.), et dans l’eczéma des mains/pieds réfractaire 69% de réduction de la gravité, 70% de réduction du score des symptômes, 87% de clair/ quasi‑clair, et une rémission moyenne de 11,3 mois (Shroff et al.). L’entreprise met en avant les bénéfices d’un traitement ciblé sans stéroïdes et une exposition UV réduite par rapport à la photothérapie corporelle.
STRATA Skin Sciences (NASDAQ: SSKN) hob am 3. Oktober 2025 belegbare Peer‑Review‑Belege hervorgehoben, die seine XTRAC® 308 nm Excimer-Laser als sichere, wirksame Therapie für lokalisiertes atopisches Ekzem validieren.
Der Pressemitteilung zufolge hat die AMA die Indikationen für Excimer‑Laser auf entzündliche und autoimmune Hauterkrankungen erweitert, wodurch eine Erstattung durch Medicare, Medicaid und private Kostenträger für das atopische Ekzem ermöglicht wird. Die PR führt klinische Ergebnisse an: 81% Juckreizminderung (Baltás et al.), Randomisierungsstudien zur Äquivalenz/Überlegenheit gegenüber Clobetasol mit längerer Haltbarkeit (Brenninkmeijer et al.), und bei refraktärem Hand-/Fußekzem 69% Reduktion der Schwere, 70% Reduktion des Symptomen-Scores, 87% Klar-/Fast-Klar-Rate und eine mittlere Remission von 11,3 Monaten (Shroff et al.). Das Unternehmen hebt Vorteile eines zielgerichteten, steroidarmen Behandlungsansatzes und eine geringere UV‑Exposition im Vergleich zur Ganzkörperphototherapie hervor.
STRATA Skin Sciences (NASDAQ: SSKN) في 3 أكتوبر 2025 أبرزت أدلة مراجعة من الأقران تثبت أن XTRAC® 308 nm Excimer Laser آمن وفعال كعلاج موضعي لالتهاب الجلد التأتبي الموضعي.
تشير النشرة إلى أن AMA قد وسعت مؤشرات ليزر الإكسيـمر إلى أمراض الجلد الالتهابية والمناعية الذاتية، مما يمكّن السداد من Medicare وMedicaid وشبكات التأمين الخاصة لالتهاب الجلد التأتبي. تورد PR النتائج السريرية: 81% انخفاض الحكة (Baltás وآخرون)، التماثل/التفوق في تجربة عشوائية مقابل الكلوبيتاسول مع دوام أطول (Brenninkmeijer وآخرون)، وفي الإكزيما المقاومة لليدين/القدمين 69% انخفاض في شدة المرض، 70% انخفاض في درجات الأعراض، 87% انخفاض في الشفافية/قربها من الشفافية، ومتوسط الانخفاض في فترة التخفيف 11.3 أشهر (Shroff وآخرون). تؤكد الشركة فائدة العلاج المستهدف الخالٍ من الستيرويدات وتقليل التعرض للأشعة فوق البنفسجية مقارنة بعلاج الضوء الكامل للجسم.
STRATA Skin Sciences (NASDAQ: SSKN) 在 2025年10月3日 突出同行评审证据，验证其 XTRAC® 308 nm Excimer Laser 作为局部特应性皮炎的安全、有效治疗方法。
新闻稿称 AMA 已将激光准分子激光的适应症扩展至炎症性和自身免疫性皮肤疾病，使 Medicare、Medicaid 及私人保险对特应性皮炎的报销成为可能。PR 引用临床结果：81% 的瘙痒减轻（Baltás 等人），随机试验在克洛必特的等效性/优越性方面具有更长的持续性（Brenninkmeijer 等人），在难治性手/足湿疹中 69% 的严重程度减少，70% 的症状评分下降，87% 的清除/接近清除，以及平均缓解期 11.3 个月（Shroff 等人）。公司强调靶向、无类固醇治疗的好处以及相较全身光疗更低的紫外线暴露。
- AMA expanded excimer indications enabling payer reimbursement (Oct 2025)
- Itch/pruritus ↓81% after one month (Baltás et al. 2006)
- Disease severity ↓69%; symptom scores ↓70% (Shroff et al. 2016)
- 87% achieved clear/almost clear skin (Shroff et al. 2016)
- Durable remission avg 11.3 months in cleared patients (Shroff et al. 2016)
- None.
HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, highlights the substantial body of peer-reviewed clinical evidence supporting the XTRAC® Excimer Laser (308 nm) as a safe, highly effective treatment for localized atopic dermatitis, the most common form of eczema. This recognition comes as the American Medical Association (AMA) has expanded excimer laser’s indications to inflammatory and autoimmune skin diseases, clearing the way for Medicare, Medicaid, and private payer reimbursement for atopic dermatitis treatment.
Dr. Dolev Rafeli, Strata’s CEO, stated, “Excimer laser treatment continues to capture market share among dermatologists because it remains effective, safe and durable. Despite the fact that this treatment has been around more than 20 years, providers, advocacy groups, academic key opinion leaders and others have advocated for it to be reimbursed across an expanded array of skin conditions, which are now being implemented across the different managed care platforms both public and private. Further, it continues to capture interest among healthcare providers who conduct independent studies that have resulted in hundreds of publications since its original approval and continue today. We continue to collaborate with these providers to optimize treatment for those patients experiencing these otherwise difficult to manage skin conditions.”
Addressing an Urgent Need
Atopic dermatitis affects more than 9.6 million children and 16.5 million adults in the United States. Beyond visible symptoms such as pain, fissures, and intense itching, the condition severely impacts daily living, sleep, work productivity, and emotional well-being. Despite its prevalence, many patients struggle with limited or ineffective treatment options.
“The excimer laser is one of our most effective treatments for localized eczema,” said Dr. Mark G. Lebwohl, M.D., Dean for Clinical Therapeutics, Professor and Chairman Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai a global leader in dermatology and phototherapy research.
Robust Clinical Evidence
- Baltás et al. (JEADV 2006, 20, 657–660)– In one of the earliest clinical trials, titled, “Treatment of atopic dermatitis with the xenon chloride excimer laser,” 15 patients with localized atopic dermatitis showed significant improvements in redness, infiltration, lichenification, and itching after just four weeks of excimer therapy. Pruritus/ itching intensity decreased by
81% after one month. Patients reported major quality-of-life improvements, and no serious side effects were observed - Brenninkmeijer et al. (British Journal of Dermatology 2010 163, pp823-831) –“Excimer laser vs. clobetasol propionate
0.05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot,” is a randomized controlled trial comparing excimer laser with clobetasol propionate ointment (the gold standard steroid therapy) found equivalent or superior results for the Excimer Laser. Follow-up data confirmed Excimer Laser provided longer-lasting improvement, with histology demonstrating reduced epidermal thickness and inflammation. This positions XTRAC® as a viable, steroid-sparing therapy - Shroff et al. (International Journal of Dermatology 2016, 55, e447–e453) – This pivotal study, titled, "Use of 308 nm excimer laser for the treatment of chronic hand and foot eczema," appears in the International Journal of Dermatology and reported on research conducted at the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, a global leader in patient care and biomedical research, and the Laboratory for Investigative Dermatology at The Rockefeller University, a world-renowned biomedical research institution. The study showed that in 30 patients with severe chronic hand and foot eczema resistant to other treatments:
69% reduction in disease severity and70% reduction in symptom scores after ~13 sessions87% achieved clear or almost clear skin- Durable remission averaging 11.3 months in patients who cleared
- Treatment was well tolerated, with only mild, sunburn-like reactions reported
Why XTRAC® Excimer Laser Stands Out
- Targeted Therapy: Directly treats diseased skin, sparing healthy tissue.
- Optimized for Difficult Areas: Especially effective for hands and feet, where creams and light boxes are less practical.
- Lower UV Exposure: Reduces cumulative UV burden compared to whole-body phototherapy.
- Convenience: Shorter treatment regimens with rapid clearance and long-lasting remission.
- Steroid Sparing: Avoids long term use of steroids.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, tariffs, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
What did STRATA (SSKN) announce on Oct 3, 2025 about XTRAC and atopic dermatitis?
How effective is XTRAC (SSKN) for itching in atopic dermatitis?
What clinical outcomes support XTRAC (SSKN) versus steroid therapy?
What results were reported for severe hand and foot eczema treated with XTRAC (SSKN)?
Does the Oct 3, 2025 PR affect reimbursement for XTRAC (SSKN)?
